Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ao, Ada ^a   Morrison, Brian J ^b,c   Wang, Heiman ^a   López, J Alejandro ^b,c   Reynolds, Brent A ^a   Lu, Jianrong ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CD24 ANTIGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HERMES ANTIGEN; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; CELL RENEWAL; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; SENSITIZATION; TARGET CELL; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; BREAST TUMOR; METABOLISM; TUMOR CELL LINE;

MUS;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 79955048946     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018810     Document Type: Article

References (35)

1. McDonnell DP, Norris JD, (2002) Connections and Regulation of the Human Estrogen Receptor. Science 296: 1642-1964.
2. Anderson WF, Chatterjee N, Ershler WB, Brawley OW, (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76: 27-36.
3. Ariazi EA, Ariazi JL, Cordera F, Jordan VC, (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6: 181-202.
4. Cleator SJ, Ahamed E, Coombes RC, Palmieri C, (2009) A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9 (Suppl): 1S6-S17.
5. Sengupta S, Jordan VC, (2008) Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 630: 206-219.
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
7. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97: 1652-1662.
8. Johnston SJ, Cheung KL, (2010) Fulvestrant- a novel endocrine therapy for breast cancer. Curr Med Chem 17: 902-914.
9. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
10. Kakarala M, Wicha MS, (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26: 2813-2820.
11. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
12. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270.
13. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
14. Phillips TM, McBride WH, Pajonk F, (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
15. Fillmore CM, Kuperwasser C, (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
16. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
17. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, et al. (2008) Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122: 298-304.
18. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, et al. (2008) Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 10: R52.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
20. Fillmore C, Kuperwasser C, (2007) Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9: 303.
21. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
22. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, et al. (2007) Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 176: 19-26.
23. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, et al. (2010) Control of mammary stem cell function by steroid hormone signaling. Nature 465: 798-802.
24. Villadsen R, Fridriksdottir AJ, Rønnov-Jessen L, Gudjonsson T, Rank F, et al. (2007) Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 177: 87-101.
25. Clarke R B, Spence K, Anderson E, Howell A, Okano H, et al. (2005) A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277: 443-456.
26. Wijayaratne AL, McDonnell DP, (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276: 35684-35692.
27. Marsaud V, Gougelet A, Maillard S, Renoir J, (2003) Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17: 2013-2027.
28. Reynolds BA, Rietze RL, (2005) Neural stem cells and neurospheres-re-evaluating the relationship. Nat Methods 2: 333-336.
29. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, et al. (2009) Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci U S A 106: 14536-14541.
30. MacCallum J, Cummings J, Dixon JM, Miller WR, (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82: 1629-1635.
31. Lin NU, Winer EP, (2008) Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol 26: 1919-1921.
32. Cianfrocca M, (2008) Overcoming recurrence risk: extended adjuvant endocrine therapy. Clin Breast Cancer 8: 493-500.
33. Harvey JM, Clark GM, Osborne CK, Allred DC, (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
34. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
35. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.